Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain

Journal of Pathology

Volumn 232, Issue 3, 2014, Pages 369-381

  Avraham, Hava Karsenty ^a   Jiang, Shuxian ^a   Fu, Yigong ^a   Nakshatri, Harikrishna ^b   Ovadia, Haim ^c   Avraham, Shalom ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

angiopoietin 2; blood brain barrier; brain microvascular endothelial cells; breast cancer metastasis in brain; tight junctions

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CLAUDIN 5; F ACTIN; PROTEIN ZO1; TREBANANIB; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN METASTASIS; BREAST METASTASIS; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; TIGHT JUNCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84892381025     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4304     Document Type: Article

References (59)

1. Steeg PS, Camphausen KA, Smith QR,. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011; 11 (5): 352-363.
2. Nguyen DX, Bos PD, Massagué J,. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9 (4): 274-284.
3. Abbott NJ, Rönnbäck L, Hansson E,. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7 (1): 41-53.
4. Dejana E., Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 2004; 5 (4): 261-270.
5. Hu G, Kang Y, Wang XF,. From breast to the brain: unraveling the puzzle of metastasis organotropism. J Mol Cell Biol 2009; 1 (1): 3-5.
6. Yilmaz M, Christofori G, Lehembre F,. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007; 13 (12): 535-541.
7. Chambers AF, Groom AC, MacDonald IC,. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
8. Goss P, Allan AL, Rodenhiser DI, et al., New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? Acta Pathol Microbiol Immunol Scand 2008; 116: 552-568.
9. Stoletov K, Strnadel J, Zardouzian E, et al., Role of connexins in metastatic breast cancer and melanoma brain colonization. J Cell Sci 2013; 126: 904-913.
10. Huber JD, Egleton RD, Davis TP,. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001; 24 (12): 719-725.
11. Hawkins BT, Davis TP,. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185.
12. Carbonell WS, Ansorge O, Sibson N, et al., The vascular basement membrane as 'soil' in brain metastasis. PLoS One 2009; 4 (6): e5857.
13. Cascone T, Heymach JV,. Targeting the angiopoietin/tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 2012; 30 (4): 441-444.
14. Mazzieri R, Pucci F, Moi D, et al., Targeting the ANG-2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19 (4): 512-526.
15. Bottsford-Miller JN, Coleman RL, Sood AK,. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012; 30 (32): 4026-4034.
16. Hashizume H, Falc̈on BL, Kuroda T, et al., Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70 (6): 2213-2223.
17. Huang H, Bhat A, Woodnutt G, et al., Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10 (8): 575-585.
18. Saharinen P, Bry M, Alitalo K,. How do angiopoietins tie in with vascular endothelial growth factors? Curr Opin Hematol 2010; 17 (3): 198-205.
19. Shim WS, Ho IA, Wong PE,. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007; 5 (7): 655-665.
20. Vates GE, Hashimoto T, Young WL, et al., Angiogenesis in the brain during development: the effects of vascular endothelial growth factor and angiopoietin-2 in an animal model. J Neurosurg 2005; 103 (1): 136-145.
21. Alitalo A, Detmar M,. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012; 31 (42): 4499-4508.
22. Jain RK,. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58-62.
23. Bos PD, Zhang XH, Nadal C, et al., Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459 (7249): 1005-1009.
24. Lockman PR, Mittapalli RK, Taskar KS, et al., Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010; 16 (23): 5664-5678.
25. Wu Z, Hofman FM, Zlokovic BV,. A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J Neurosci Methods 2003; 130 (1): 53-63.
26. Lu TS, Avraham HK, Seng S, et al., Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol 2008; 181 (9): 6406-6416.
27. Barlow AL, Macleod A, Noppen S, et al., Colocalization analysis in fluorescence micrographs: verification of a more accurate calculation of Pearson's correlation coefficient. Microsc Microanal 2010; 16: 710-724.
28. Herbst RS, Hong D, Chap L, et al., Safety, pharmacokinetics, and antitumor activity of Trebananib, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27 (21): 3557-3565.
29. Rini B, Szczylik C, Tannir NM, et al., Trebananib in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012; 118 (24): 6152-6161.
30. Goede V, Coutelle O, Neuneier J, et al., Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010; 103 (9): 1407-1414.
31. Helfrich I, Edler L, Sucker A, et al., Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15 (4): 1384-1392.
32. Lovegrove FE, Tangpukdee N, Opoka RO, et al., Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLos One 2009; 4 (3): 34912.
33. Park JH, Park KJ, Kim YS, et al., Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007; 132 (1): 200-206.
34. Rykala J, Przybylowska K, Majsterek I, et al., Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011; 17 (4): 809-817.
35. Schulz P, Fischer C, Detjen KM, et al., Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J 2011; 25 (10): 3325-3335.
36. De Vries HE, Kuiper J, De Boer AG, et al., The blood-brain barrier in neuroinflammatory disease. Pharmacol Rev 1997; 49 (2): 143-155.
37. Zhang ZG, Zhang L, Jiang Q, et al., VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106 (7): 829-838.
38. Fuxe J, Lashnits E, O'Brien S, et al., Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation. Am J Pathol 2010; 176 (4): 2009-2018.
39. Lewis CE, Hughes R,. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res 2007; 9 (3): 209.
40. Nasarre P, Thomas M, Kruse K, et al., Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009; 69 (4): 1324-1333.
41. Zadeh G, Qian B, Okhowat A, et al., Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol 2004; 164 (2): 467-476.
42. Zhu Y, Lee C, Shen F, et al., Angiopoietin-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke 2005; 36 (7): 1533-1537.
43. Bhat-Nakshatri P, Wang G, Appaiah H, et al., AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Mol Cell Biol 2008; 28 (24): 7487-7503.
44. Gökmen-Polar Y, Nakshatri H, Badve S,. Biomarkers for breast cancer stem cells: the challenges ahead. Biomark Med 2011; 5 (5): 661-671.
45. Patel JB, Appaiah HN, Burnett RM, et al., Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene 2011; 30 (11): 1290-1301.
46. Bhat-Nakshatri P, Wang G, Collins NR, et al., Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 2009; 37 (14): 4850-4861.
47. Cancer Genome Atlas Network,. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490 (7418): 61-70.
48. Daly C, Eichten A, Castanaro C, et al., Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73 (1): 108-118.
49. Polyak, K., Heterogeneity in breast cancer. J Clin Invest 2011; 121 (10): 3786-3788.
50. Chae SS, Kamoun WS, Farrar CT, et al., Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010; 16 (14): 3618-3627.
51. Holash J, Wiegand SJ, Yancopoulos GD,. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18 (38): 5356-5362.
52. Küsters B, Leenders WP, Wesseling P, et al., Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002; 62 (2): 341-345.
53. Lobov IB, Brooks PC, Lang RA,. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99 (17): 11205-11210.
54. Fiedler U, Reiss Y, Scharpfenecker M, et al., Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006; 12 (2): 235-239.
55. Zhang L, Yang N, Park JW, et al., Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63 (12): 3403-3412.
56. Szekanecz Z, Koch AE,. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007; 3 (11): 635-643.
57. Boje KM,. In vivo measurement of blood-brain barrier permeability. Curr Protoc Neurosci 2001; 7: unit 7. 19.
58. Erier JT,., Bennewith KL, Cox TR, et al., Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44.
59. Kaplan RN, Riba RD, Zacharoulis S, et al., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.